Those who have been on traditional GLP-1 medications may use Semaglutide + Glycine to transition to a lower-dose maintenance treatment
Wegovy is approved for use in non-diabetic adults with a BMI of 30 or greater, or those with a BMI of 27 or greater with weight-related medical problems such as high blood pressure or high cholesterol
GHRP-2 and GHRP-6 Monitoring in liver disease / IGF-1, ALT, AST, albumin every 4 to 6 weeks Regulatory status / 503A compounded prescription only
Integration of O-GlcNAc into stress response pathways
The STEP 1 trial extension followed participants for a year after semaglutide was withdrawn and found that, on average, around two-thirds of the weight lost was regained
The most common electrolyte imbalances include hypokalaemia (low potassium), hyponatraemia (low sodium), and hypomagnesaemia (low magnesium), typically resulting from gastrointestinal losses through vomiting or diarrhoea and reduced dietary intake due to appetite suppression
